The Delhi High Court on Monday extended its interim order lifting ban on fixed dose combination (FDC) medicines of some pharmaceutical companies, which had got relief last week, till March 28.
Several other pharma companies, which also filed appeals against the Centre’s notification, were not granted a similar relief but have been given “assurance” that no coercive action will be taken against them till the next date of hearing.
- Banning combination drugs: A high-stakes case in point
- How and why Delhi High Court revoked ban on 344 popular drugs
- Delhi HC quashes ban on 344 fixed dose combination medicines
- Madras HC differs with Delhi HC on ban on some FDC drugs
- Ban on sale of 344 drugs: Delhi HC to resume hearing pleas against Centre's order
- Ban on drugs like Vicks and Corex: Nothing sudden about it
In an affidavit, the government said that lifting the ban would be “against public interest and patient safety”. It claimed that the pharma companies were interested only in profit.
As of Monday, 112 petitions had been filed before the Delhi HC challenging the Centre’s March 10 notification banning more than 300 FDC drugs. The companies claim that the notification was issued without following the due process of issuing them a show-cause notice or hearing them.
The court had last week stayed operation of the Centre’s ban on some FDC drugs of 30 pharma companies. ENS